Bionexus Gene Lab Stock Analysis

BioNexus Stock Analysis Notes

About 36.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.74. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioNexus Gene Lab has Price/Earnings (P/E) ratio of 350.0. The entity recorded a loss per share of 1.28. The firm had not issued any dividends in recent years. BioNexus Gene had 1:10 split on the 7th of April 2025. BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additional office in Sheridan, Wyoming. Bionexus Gene operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 27 people. For more info on BioNexus Gene Lab please contact SuLeng Tan at 60 1 307 241 6898 or go to https://www.bionexusgenelab.com.

BioNexus Gene Lab Investment Alerts

BioNexus Gene Environmental, Social, and Governance (ESG) Scores

BioNexus Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.2 M.

BioNexus Profitablity

The company has Profit Margin (PM) of (0.24) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.3) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.3.

Management Efficiency

BioNexus Gene Lab has return on total asset (ROA) of (0.1643) % which means that it has lost $0.1643 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2835) %, meaning that it created substantial loss on money invested by shareholders. BioNexus Gene's management efficiency ratios could be used to measure how well BioNexus Gene manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.14. In addition to that, Return On Capital Employed is expected to decline to -0.22. At present, BioNexus Gene's Debt To Assets are projected to slightly decrease based on the last few years of reporting.

Technical Drivers

As of the 18th of February 2026, BioNexus Gene shows the Mean Deviation of 3.24, risk adjusted performance of (0.21), and Standard Deviation of 4.39. BioNexus Gene Lab technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

BioNexus Gene Lab Price Movement Analysis

BioNexus Gene Lab Insider Trading Activities

BioNexus Gene Outstanding Bonds

BioNexus Gene Predictive Daily Indicators

BioNexus Gene Forecast Models

BioNexus Gene's time-series forecasting models are one of many BioNexus Gene's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioNexus Gene's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

BioNexus Gene Bond Ratings

BioNexus Gene Lab financial ratings play a critical role in determining how much BioNexus Gene have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for BioNexus Gene's borrowing costs.

BioNexus Gene Lab Debt to Cash Allocation

BioNexus Gene Lab currently holds 210.56 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. BioNexus Gene Lab has a current ratio of 3.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BioNexus Gene's use of debt, we should always consider it together with its cash and equity.

BioNexus Gene Total Assets Over Time

BioNexus Gene Assets Financed by Debt

The debt-to-assets ratio shows the degree to which BioNexus Gene uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

BioNexus Gene Debt Ratio

2.86

It looks as if most of the BioNexus Gene's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the BioNexus Gene's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of BioNexus Gene, which in turn will lower the firm's financial flexibility.

BioNexus Gene Corporate Bonds Issued

BioNexus Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how BioNexus Gene prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioNexus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioNexus Gene. By using and applying BioNexus Stock analysis, traders can create a robust methodology for identifying BioNexus entry and exit points for their positions.

When running BioNexus Gene's price analysis, check to measure BioNexus Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNexus Gene is operating at the current time. Most of BioNexus Gene's value examination focuses on studying past and present price action to predict the probability of BioNexus Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNexus Gene's price. Additionally, you may evaluate how the addition of BioNexus Gene to your portfolios can decrease your overall portfolio volatility.